Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5NETWORK 2OTHER_GOV 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 30Leukemia, Lymphocytic, Chronic, B-Cell 28Leukemia 26Lymphoma 19Leukemia, Myeloid, Acute 18Myelodysplastic Syndromes 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Multiple Myeloma 15Neoplasm Metastasis 13Lymphoma, Follicular 12Skin Neoplasms 11Lymphoma, Mantle-Cell 10Leukemia, Myelomonocytic, Chronic 10Leukemia, Myeloid, Accelerated Phase 10Hodgkin Disease 10Congenital Abnormalities 10Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Myeloproliferative Disorders 8Blast Crisis 8Anemia, Refractory, with Excess of Blasts 8Neoplasms, Plasma Cell 7Lymphoma, Large B-Cell, Diffuse 7Kidney Neoplasms 7Burkitt Lymphoma 7Primary Myelofibrosis 6Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 6Lymphoma, Large-Cell, Immunoblastic 6

Interventions

Lenalidomide 3Melphalan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dexamethasone 2Bortezomib 2sargramostim 1ixazomib 1fludarabine phosphate 1fludarabine 1Voriconazole 1Thalidomide 1Sugars 1Stem Cell Transplantation 1Platelet Transfusion 1Leukapheresis 1Fluconazole 1Cyclophosphamide 1Colony-Stimulating Factors 1Calcium Dobesilate 1Bone Marrow Transplantation 1Blood Specimen Collection 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Diseases × fludarabine phosphate × Clear all
NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
57 enrolled 22 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡